GlaxoSmithKline

Rank in 2013: 1st
Community Size: 4th
Activity: 7th
Engagement: 10th
Virality: 6th

GlaxoSmithKline ($GSK) dropped from the top spot in Ogilvy's assessment last year to the middle of the pack this year, mainly because of lagging engagement--where it dropped to the bottom of the rankings--and activity, where it landed in the middle of the 14 companies.

On the plus side, GSK's Facebook posts are very visual with almost every post sporting a photo, infographic or video--which isn't always the case in pharma social media. Its YouTube channel also seems to be regularly stocked with fresh video, and it boasts a fairly active Flickr stream, which it mentions in its policy page as a photo and infographic source for journalists and others. With activity and engagement measured as an average over a three-week period chosen by Ogilvy, could it be that GSK was uncharacteristically lacking in posts and re-tweets during those weeks?

In a recent study from consultancy Radley Yeldar, in fact, GSK's social media efforts ranked in the top 10 of all of London's largest FTSE 100 companies, with a "standout" rating and the mention of social media as a strong suit for the company. GSK was given a much higher score than many more consumer-facing businesses, such as supermarket chain Morrisons and television network ITV. 

For more:
GSK, bioCSL to increase flu vaccine deliveries to U.S.
Reuters: WHO, EMA likely to approve GlaxoSmithKline's malaria vaccine despite challenges
Two agency giants duke it out for GlaxoSmithKline $900M media account
GSK's big, bad whooping cough vaccination campaign bares its teeth
GlaxoSmithKline and Purdue look to Apple's ResearchKit for R&D

GlaxoSmithKline
Read more on

Suggested Articles

When it comes to online health information, user experience is a top metric to focus on—but why? Learn how good UX can make your brand more impactful.

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Zolgensma hauled in $160 million in its first full quarter on the market, more than 60% above the Street's expectations.